311 - Oral Abstracts Session
Towards personalization in kidney transplant

Tuesday September 13, 2022 | 11:35 to 13:05
Room: C2
Track: Transplantation Immunosuppression

Description

For attending this session, you can claim 1.5 EACCME credits

Presentations

Dr. Soufian Meziyerh, Netherlands
Real-life tacrolimus levels are associated with biopsy-proven acute rejection after the first year post-kidney transplantation

Dr. Soufian Meziyerh, Netherlands
Early Tacrolimus exposure is associated with BK-viremia in kidney transplant recipients

Dr. David Rush, Canada
A 5-year prospective, randomized, open-label study of standard versus low-dose prolonged-release tacrolimus with or without ACEi/ARB in kidney transplantation

Dr. Aileen C Johnson, United States
Every 2-month belatacept maintenance therapy in kidney transplant recipients: 3-year follow-up of a randomized, non-inferiority trial

Dr. Christophe Masset, France
Modelling of kidney allograft function depending on Fast Tacrolimus Metabolizer status at different times post-transplantation

Ms. Aline L van Rijn, Netherlands
The effect of tacrolimus and mycophenolic acid on TTV loads in kidney transplant recipients

Dr. Samy M Riad, United States
Outcomes of preemptive second kidney transplant by induction type in the United States



© 2024 TTS 2022